Barbara Klencke - 20 Jan 2023 Form 4 Insider Report for eFFECTOR Therapeutics, Inc. (EFTR)

Role
Director
Signature
/s/ Michael Byrnes, Attorney-in-Fact for Barbara Klencke
Issuer symbol
EFTR
Transactions as of
20 Jan 2023
Net transactions value
$0
Form type
4
Filing time
24 Jan 2023, 15:10:50 UTC
Previous filing
01 Jul 2022
Next filing
10 Apr 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EFTR Stock Option (Right to Buy) Award $0 +28,125 $0.000000 28,125 20 Jan 2023 Common Stock 28,125 $0.4688 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option will vest in substantially equal monthly installments over 12 months, commencing on January 20, 2023, subject to the Reporting Person's continued service with the Issuer through each vesting date.